AURKC — patent landscape

Top predicted compounds (top 20 by supporting neighbours, then confidence)

Compound	Confidence	Supporting neighbours
SCHEMBL62264	0.51	3/20
Danusertib (SCHEMBL466509)	1.00	2/20
SCHEMBL75631	0.76	2/20
SCHEMBL75584	0.75	2/20
SCHEMBL145151	0.63	2/20
SCHEMBL139972	0.63	2/20
SCHEMBL145763	0.63	2/20
SCHEMBL91082	0.62	2/20
SCHEMBL148432	0.62	2/20
SCHEMBL139643	0.61	2/20
SCHEMBL142235	0.61	2/20
SCHEMBL75646	0.61	2/20
SCHEMBL91081	0.61	2/20
SCHEMBL145814	0.58	2/20
SCHEMBL144801	0.57	2/20
SCHEMBL61900	0.56	2/20
SCHEMBL144133	0.55	2/20
SCHEMBL143571	0.53	2/20
SCHEMBL146251	0.53	2/20
SCHEMBL145105	0.53	2/20

Clinical trials — most relevant to AURKC by text similarity (a relevance ranking, not an exhaustive list)

Trial	Phase	Status
Study of MLN8237 in Combination With Irinotecan and Temozolomide	PHASE1/PHASE2	COMPLETED
Alisertib in Treating Patients With Relapsed or Refractory Peripheral T-Cell Non-Hodgkin Lymphoma	PHASE2	COMPLETED
Phase II Trial of Alisertib With Induction Chemotherapy in High-risk AML	PHASE2	COMPLETED
Aurora Kinase Inhibitor LY3295668 in Combination With Osimertinib for the Treatment of Advanced or Metastatic EGFR-Mutant Non-squamous Non-small Cell Lung Cancer	PHASE1/PHASE2	ACTIVE_NOT_RECRUITING
Atezolizumab Immunotherapy, in Immunotherapy Naive Patients With Urinary Tract Squamous Cell Carcinoma (UTSCC).	PHASE2	UNKNOWN
Aurora A Kinase Inhibitor MLN8237 and Bortezomib in Treating Patients With Relapsed or Refractory Multiple Myeloma	PHASE1/PHASE2	COMPLETED
Everolimus in CDK12-Deficient Metastatic Colorectal Cancer (EVER-RECODE)	PHASE1/PHASE2	NOT_YET_RECRUITING
I/II Phase Study Evaluating M1774 in Combination With Fulvestrant in HR+ and HER2- Advanced Breast Cancers	PHASE1/PHASE2	NOT_YET_RECRUITING
Abemaciclib With or Without Atezolizumab for mCRPC	PHASE2	COMPLETED
Bryostatin 1 in Treating Patients With Metastatic or Recurrent Head and Neck Cancer	PHASE2	COMPLETED
Aurora B/C Kinase Inhibitor GSK1070916A in Treating Patients With Advanced Solid Tumors	PHASE1	COMPLETED
Alisertib in Combination With Osimertinib in Metastatic EGFR-mutant Lung Cancer	PHASE1	RECRUITING
AT9283 in Children and Adolescents With Relapsed and Refractory Solid Tumors	PHASE1	COMPLETED
Alisertib and Romidepsin in Treating Patients With Relapsed or Refractory B-Cell or T-Cell Lymphomas	PHASE1	COMPLETED
Alisertib and Combination Chemotherapy in Treating Patients With Gastrointestinal Tumors	PHASE1	COMPLETED
A Study of MLN8237, a Novel Aurora A Kinase Inhibitor, in Participants With Advanced Solid Tumors	PHASE1	COMPLETED
AZD1775 for Advanced Solid Tumors	PHASE1	COMPLETED
Phase 1 Study Of Aurora Kinase Inhibitor PF-03814735 In Patients With Advanced Solid Tumors	PHASE1	COMPLETED
Veliparib (ABT-888), an Oral PARP Inhibitor, and VX-970, an ATR Inhibitor, in Combination With Cisplatin in People With Refractory Solid Tumors	PHASE1	COMPLETED
Phase I Study of Oral BAY 1217389 in Combination With Intravenous Paclitaxel	PHASE1	COMPLETED
Auranofin and Sirolimus in Treating Patients With Advanced Solid Tumors or Recurrent Non-Small Cell Lung Cancer	PHASE1	WITHDRAWN
Aurora Kinase Inhibitor AT9283 in Treating Patients With Advanced or Metastatic Solid Tumors or Non-Hodgkin's Lymphoma	PHASE1	COMPLETED
Phase I Study to Assess the Safety, Pharmacokinetics, & Pharmacodynamics of GSK923295 in Subjects w/ Refractory Cancer	PHASE1	COMPLETED
Open-Label, Randomised, Multi-Drug, Biomarker-Directed, Phase 1b Study in Pts w/ Muscle Invasive Bladder Cancer	PHASE1	ACTIVE_NOT_RECRUITING
Adavosertib and Local Radiation Therapy in Treating Children With Newly Diagnosed Diffuse Intrinsic Pontine Gliomas	PHASE1	COMPLETED
A Safety, Tolerability and PK Study of DCC-2618 in Patients With Advanced Malignancies	PHASE1	COMPLETED
Study of ABT-751 in Patients With Refractory Hematologic Malignancies	PHASE1	COMPLETED
Defining the Triple Negative Breast Cancer Kinome Response to GSK1120212	EARLY_PHASE1	COMPLETED
AURORA: Aiming to Understand the Molecular Aberrations in Metastatic Breast Cancer.	nan	RECRUITING
Phosphoproteomic Patterns as a Novel Biomarker for Aurora and Polo-like Kinase Inhibitors in Non-Small Cell Lung Cancer	nan	COMPLETED

Related proteins — ESM-2 sequence neighbours (a AURKC binder may also engage these)

Protein	Name	Similarity
O70126	—	0.999	O70126 →
Q6NW76	—	0.998	Q6NW76 →
Q9M077	—	0.997	Q9M077 →
A4IGM9	—	0.997	A4IGM9 →
AURKB	Aurora kinase B	0.995	landscape →
Q7YRC6	—	0.993	Q7YRC6 →
Q63531	—	0.992	Q63531 →
Q384J7	—	0.992	Q384J7 →
Q9VKN7	—	0.991	Q9VKN7 →
P10665	—	0.990	P10665 →
RPS6KA1	Ribosomal protein S6 kinase alpha-1	0.990	landscape →
Q9N0X0	—	0.990	Q9N0X0 →
Q61XD3	—	0.989	Q61XD3 →
Q6GPL3	—	0.989	Q6GPL3 →
O01427	—	0.989	O01427 →
Q6PFQ0	—	0.988	Q6PFQ0 →
O55099	—	0.988	O55099 →
Q755C4	—	0.988	Q755C4 →
Q683C9	—	0.988	Q683C9 →
PNCK	Calcium/calmodulin-dependent protein kinase type 1B	0.988	landscape →
RPS6KA2	Ribosomal protein S6 kinase alpha-2	0.987	landscape →
P18653	—	0.987	P18653 →
O88445	—	0.987	O88445 →
RPS6KA6	Ribosomal protein S6 kinase alpha-6	0.987	landscape →
O59790	—	0.987	O59790 →
P10666	—	0.987	P10666 →
Q6DE08	—	0.987	Q6DE08 →
P18654	—	0.986	P18654 →
RPS6KA3	Ribosomal protein S6 kinase alpha-3	0.986	landscape →
E2RTQ7	—	0.985	E2RTQ7 →